Evidence map›Paper›PMID 35836253›Full record

ArticleBreast cancer research : BCR2022

Upregulation of Nox4 induces a pro-survival Nrf2 response in cancer-associated fibroblasts that promotes tumorigenesis and metastasis, in part via Birc5 induction.

Shakeel Mir, Briana D Ormsbee Golden, Brandon J Griess, Raghupathy Vengoji, Eric Tom, Elizabeth A Kosmacek, Rebecca E Oberley-Deegan, Geoffrey A Talmon, Vimla Band, Melissa Lt Teoh-Fitzgerald

Open access · goldAbstract read
In one paragraph

Article in Breast cancer research : BCR, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 30 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Research progress on the expression characteristics, biological functions, and therapeutic potential of NOX4 in malignant tumors: a functional perspective.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  5. The Pro-Metastatic Roles of ROS.Antioxidants (Basel, Switzerland) · 2026
    Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Thiophene-based water-soluble CBiomaterials translational · 2025
    Article
  13. Proactive and reactive roles of TGF-β in cancer.Seminars in cancer biology · 2023
    Review
  14. Article
  15. Review
  16. Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Shakeel Mir *Department of Biochemistry and Molecular Biology, Buffett Cancer Center, College of Medicine, University of Nebraska Medical Center, 7005 Durham Research Center, 985870 Nebraska Medical Center, Omaha, NE, 68198, USA.
Briana D Ormsbee GoldenDepartment of Biochemistry and Molecular Biology, Buffett Cancer Center, College of Medicine, University of Nebraska Medical Center, 7005 Durham Research Center, 985870 Nebraska Medical Center, Omaha, NE, 68198, USA.
Brandon J GriessDepartment of Biochemistry and Molecular Biology, Buffett Cancer Center, College of Medicine, University of Nebraska Medical Center, 7005 Durham Research Center, 985870 Nebraska Medical Center, Omaha, NE, 68198, USA.
Raghupathy VengojiDepartment of Biochemistry and Molecular Biology, Buffett Cancer Center, College of Medicine, University of Nebraska Medical Center, 7005 Durham Research Center, 985870 Nebraska Medical Center, Omaha, NE, 68198, USA.
Eric TomDepartment of Biochemistry and Molecular Biology, Buffett Cancer Center, College of Medicine, University of Nebraska Medical Center, 7005 Durham Research Center, 985870 Nebraska Medical Center, Omaha, NE, 68198, USA.
Elizabeth A KosmacekDepartment of Biochemistry and Molecular Biology, Buffett Cancer Center, College of Medicine, University of Nebraska Medical Center, 7005 Durham Research Center, 985870 Nebraska Medical Center, Omaha, NE, 68198, USA.
Rebecca E Oberley-DeeganDepartment of Biochemistry and Molecular Biology, Buffett Cancer Center, College of Medicine, University of Nebraska Medical Center, 7005 Durham Research Center, 985870 Nebraska Medical Center, Omaha, NE, 68198, USA.
Geoffrey A TalmonDepartment of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, 68198, USA.
Vimla BandDepartment of Genetics, Cell Biology and Anatomy, Buffett Cancer Center, College of Medicine, University of Nebraska Medical Center, Omaha, NE, 68198, USA.
Melissa Lt Teoh-FitzgeraldDepartment of Biochemistry and Molecular Biology, Buffett Cancer Center, College of Medicine, University of Nebraska Medical Center, 7005 Durham Research Center, 985870 Nebraska Medical Center, Omaha, NE, 68198, USA. m.teohfitzgerald@unmc.edu.
University of Nebraska Medical Center · US

Funding

Women's Cancer Research ProgramP30CA014236 · NCI · DUKE UNIVERSITY · PI Laura Fish · 1985 to 2026
$174.8M
UNMC Structural Biology CoreP20GM103427 · NIGMS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Heather Colleen Jensen-Smith · 2012 to 2026
$59.2M
UNMC/EPPLEY CANCER CENTER SUPPORT GRANTP30CA036727 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI James Eudy · 1985 to 2026
$55.0M
CHEMICAL CARCINOGENESIS &CANCER BIOLOGYT32CA009476 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Jennifer D. Black · 1988 to 2026
$6.2M
Research Pilot Project ProgramP30GM106397 · NIGMS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI JOHNSON, KEITH R · 2013 to 2017
$4.9M
Extracellular Redox Signaling in mammary tumor-fibroblast interactionsR01CA182086 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI TEOH, MELISSA LAI TEE · 2014 to 2018
$1.5M
NCI NIH HHS P30 CA014236NCI NIH HHS P30 CA036727NCI NIH HHS R01 CA182086NCI NIH HHS T32 CA009476NIGMS NIH HHS P20 GM103427NIGMS NIH HHS P30 GM106397
6 · The paper itself

Abstract

backgroundA pro-oxidant enzyme, NADPH oxidase 4 (Nox4) has been reported to be a critical downstream effector of TGFβ-induced myofibroblast transformation during fibrosis. While there are a small number of studies suggesting an oncogenic role of Nox4 derived from activated fibroblasts, direct evidence linking this pro-oxidant to the tumor-supporting CAF phenotype and the mechanisms involved are lacking, particularly in breast cancer.

methodsWe targeted Nox4 in breast patient-derived CAFs via siRNA-mediated knockdown or administration of a pharmaceutical inhibitor (GKT137831). We also determine primary tumor growth and metastasis of implanted tumor cells using a stable Nox4-/- syngeneic mouse model. Autophagic flux of CAFs was assessed using a tandem fluorescent-tagged ptfl-LC3 plasmid via confocal microscopy analysis and determination of the expression level of autophagy markers (beclin-1 and LC3B). Nox4 overexpressing CAFs depend on the Nrf2 (nuclear factor-erythroid factor 2-related factor 2) pathway for survival. We then determined the dependency of Nox4-overexpressing CAFs on the Nrf2-mediated adaptive stress response pathway for survival. Furthermore, we investigated the involvement of Birc5 on CAF phenotype (viability and collagen contraction activity) as well as the expression level of CAF markers, FAP and αSMA.

conclusionsWe found that deletion of stroma Nox4 and pharmaceutically targeting its activity with GKT137831 significantly inhibited orthotopic tumor growth and metastasis of implanted E0771 and 4T1 murine mammary carcinoma cell lines in mice. More importantly, we found a significant upregulation of Nox4 expression in CAFs isolated from human breast tumors versus normal mammary fibroblasts (RMFs). Our in situ RNA hybridization analysis for Nox4 transcription on a human breast tumor microarray further support a role of this pro-oxidant in the stroma of breast carcinomas. In addition, we found that Nox4 promotes autophagy in CAFs. Moreover, we found that Nox4 promoted survival of CAFs via activation of Nrf2, a master regulator of oxidative stress response. We have further shown Birc5 is involved as a downstream modulator of Nrf2-mediated pro-survival phenotype. Together these studies indicate a role of redox signaling via the Nox4-Nrf2 pathway in tumorigenesis and metastasis of breast cancer cells by promoting autophagy and survival of CAFs.

Indexed as

Breast NeoplasmsCancer-Associated FibroblastsAnimalsCarcinogenesisCell Line, TumorFemaleFibroblastsHumansMiceNADPH Oxidase 4NF-E2-Related Factor 2Reactive Oxygen SpeciesSurvivinUp-RegulationBIRC5 protein, humanNADPH Oxidase 4NF-E2-Related Factor 2NOX4 protein, humanNox4 protein, mouseReactive Oxygen SpeciesSurvivinAdaptive stress response pathwayAutophagyBreast cancer progression and metastasisCAF survivalCancer-associated fibroblastsNADPH Oxidase 4Nuclear factor-erythroid factor 2-related factor 2Pro-oxidant

Identifiers

PMID35836253
PMCPMC9281082
OpenAlexW4285388630

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.